A 28-year-old woman presents with a sudden eruption of painful, monomorphic sterile pustules on erythematous skin covering 60 percent of her body surface area, accompanied by fever. Genetic testing confirms a mutation in the IL36RN gene. Which targeted biologic is specifically approved for this condition?
- A Spesolimab ✓
- B Anifrolumab
- C Teplizumab
- D Guselkumab
Correct answer: A. Spesolimab
Explanation
Spesolimab is a monoclonal antibody targeting the interleukin-36 receptor, specifically approved for generalized pustular psoriasis (GPP), which is often associated with IL36RN mutations. Anifrolumab targets the type I interferon receptor for lupus, teplizumab targets CD3 for type 1 diabetes, and guselkumab targets IL-23 p19 for plaque psoriasis.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.